Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Phase I trial of the farnesyl protein transferase (FPTASE) inhibitor L-778123 on a 14 or 28-day dosing schedule

Phase I trial of the farnesyl protein transferase (FPTASE) inhibitor L-778123 on a 14 or 28-day dosing schedule. Journal of Clinical Oncology, ASCO Annual Meeting Proceedings. 2000.


© 2022 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.